Scheithauer W, Schmiegel W
Bevacizumab plus oxaliplatin-based regimens for the treatment of colorectal cancer. [Journal Article, Research Support, Non-U.S. Gov't]
Onkologie 2009 Jul; 32(7):431-9.
The anti-angiogenic, monoclonal antibody bevacizumab, in combination with chemotherapy, is proven to prolong survival in metastatic colorectal cancer. Recent data demonstrate that combining bevacizumab with widely used oxaliplatin-containing chemotherapy regimens is a promising strategy for further improving patient outcomes.
More from this journal |
